NCT03756298View on ClinicalTrials.gov

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

284

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2027

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

Atezolizumab

Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)

DRUG

Capecitabine

capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)

Trial Locations (1)

08308

Korea University, Guro hospital, Seoul

All Listed Sponsors

lead

National Cancer Center, Korea

OTHER_GOV

NCT03756298 - Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | Biotech Hunter | Biotech Hunter